{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_2",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Chelator Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_4",
        "name": "Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_5",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_6",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_7",
        "name": "Tetrathiomolybdate Washout",
        "type": "Before",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_8",
        "name": "Alcohol Abstinence Pre-Dose",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 48,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_9",
        "name": "Outpatient Dosing Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 0,
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_10",
        "name": "Pregnancy Test Interval",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_11",
        "name": "Run-in Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_12",
        "name": "Baseline Collection Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_13",
        "name": "15 mg/day Dosing Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_14",
        "name": "30 mg/day Dosing Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_15",
        "name": "CRU Re-admission Window",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22,
        "relativeTo": "First Dose"
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Safety Review for Dose Titration",
        "instanceType": "Condition",
        "description": "Safety Review Committee (SRC) must review available safety data through Day 23 for each participant before dose titration.",
        "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_2",
        "name": "Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "The Outpatient Period may be extended for up to 14 additional days with Investigator approval.",
        "text": "To ensure flexibility, the Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      },
      {
        "id": "cond_3",
        "name": "ALT/AST Elevation (> 5x ULN)",
        "instanceType": "Condition",
        "description": "Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is greater than 5 times the upper limit of normal (ULN).",
        "text": "ALT/AST > 5 × ULN"
      },
      {
        "id": "cond_4",
        "name": "ALT/AST Elevation (> 3 to 5x ULN)",
        "instanceType": "Condition",
        "description": "Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is greater than 3 times and up to 5 times the upper limit of normal (ULN).",
        "text": "ALT/AST > 3 to 5 × ULN"
      },
      {
        "id": "cond_5",
        "name": "Potential Liver Injury (Hy's Law)",
        "instanceType": "Condition",
        "description": "Bilirubin is greater than 2 times ULN, accompanied by ALT greater than 3 times ULN.",
        "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN, indicative of liver injury"
      },
      {
        "id": "cond_6",
        "name": "Anemia Trigger",
        "instanceType": "Condition",
        "description": "Hemoglobin is less than 10 g/dL or has decreased by more than 2 g/dL from baseline.",
        "text": "Hemoglobin < 10 g/dL or > 2 g/dL ↓ from baseline"
      },
      {
        "id": "cond_7",
        "name": "Thrombocytopenia Trigger",
        "instanceType": "Condition",
        "description": "Platelets are less than 100,000/mm3 or have decreased by more than 30% from baseline.",
        "text": "Platelets < 100,000/mm3 or > 30% ↓ from baseline"
      },
      {
        "id": "cond_8",
        "name": "Neutropenia Trigger",
        "instanceType": "Condition",
        "description": "Neutrophils have decreased by more than 30% from baseline and are below the reference range.",
        "text": "Neutrophils > 30% ↓ from baseline and below reference range at baseline"
      },
      {
        "id": "cond_9",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Evidence of neurologic worsening by Adverse Events or by neurologic physical exam assessment.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_10",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis.",
        "text": "Evidence of clinically significant acute psychiatric worsening"
      },
      {
        "id": "cond_11",
        "name": "Rechallenge Limit",
        "instanceType": "Condition",
        "description": "A maximum of 3 rechallenges will be allowed following dose modification or interruption.",
        "text": "A maximum of 3 rechallenges will be allowed."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Titration to 30 mg/day",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "Following the Run-in Period, participants will be administered ALXN1840 at 15 mg/day for a treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29."
      },
      {
        "id": "trans_2",
        "name": "Dose Interruption for ALT/AST > 3-5x ULN",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT/AST is > 3 to 5 x ULN, temporarily interrupt dosing. Rechallenge at 15 mg QOD when ALT/AST is < 3 x ULN."
      },
      {
        "id": "trans_3",
        "name": "Discontinuation for ALT/AST > 5x ULN",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT/AST is > 5 x ULN, discontinue ALXN1840. Rechallenge is not recommended."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Hematologic Abnormalities",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "For specified decreases in Hemoglobin, Platelets, or Neutrophils, reduce dose to previous dose level or to 15 mg QOD if on 15 mg QD."
      },
      {
        "id": "trans_5",
        "name": "Dose Interruption for Potential Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2x ULN and ALT > 3x ULN, temporarily interrupt dosing. Rechallenge at 15 mg QOD or less when bilirubin is below ULN, with Medical Monitor approval."
      },
      {
        "id": "trans_6",
        "name": "Dose Modification for Neurologic/Psychiatric Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on neurologic or psychiatric worsening."
      },
      {
        "id": "trans_7",
        "name": "General Discontinuation Criteria",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for: Serious hypersensitivity reaction; Severe uncontrolled infection; Use of disallowed medication; Pregnancy or planned pregnancy."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Participant Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_2",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_3",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site after documented attempts."
      },
      {
        "id": "exit_4",
        "name": "Sponsor-Initiated Study Termination",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of Alexion."
      },
      {
        "id": "exit_5",
        "name": "Site Closure",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A study site may be closed early for reasons including failure to comply with protocol, inadequate recruitment, or discontinuation of study intervention development."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "pt_day23_review",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point prior to Day 29 based on safety data review through Day 23 to determine if participant can titrate from 15 mg/day to 30 mg/day.",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "Ongoing Safety-Based Dose Modification",
        "timepointId": "pt_ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing monitoring for safety events that trigger dose modification (interruption, reduction) or discontinuation as per protocol criteria.",
        "conditionIds": [
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_8",
          "cond_9",
          "cond_10"
        ]
      }
    ],
    "summary": {
      "timingCount": 15,
      "conditionCount": 11,
      "transitionRuleCount": 7,
      "exitCount": 5
    }
  }
}